11d agoThe FlyBULLISH 67Earnings
Archived explainer. For the current picture see today's MMED page.
Why Is MINIMED GROUP INC (MMED) Stock Up Today?
By the Top Tier Newswire AI Desk · September 1, 2026 at 11:38 AM ET · reviewed against 11 wire stories
MINIMED GROUP INC (MMED) is up +11.48% in the latest session. Our newswire has captured 11 stories on MMED across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why MMED stock is up today
MiniMed Group Inc (MMED) surged 11.48% to $22.59 in early trading on September 1, 2026, driven by the company's raised fiscal 2027 organic growth outlook and strong first-quarter results. The stock opened with a small gap down but quickly reversed course to hit a session high of $22.62. The rally followed the release of Q1 earnings and a revised revenue forecast that exceeded expectations.
What Happened
MiniMed reported Q1 fiscal 2027 revenue of $843 million, with organic growth of 15.8%. The company raised its full-year organic growth outlook to approximately 10.5%, citing momentum in its Flex insulin-delivery product and progress toward a U.S. launch of Fit by summer 2027. The CEO, Que Dallara, described the quarter as an excellent start to the fiscal year. The stock’s strong performance also came after StoneX reiterated a Buy rating on the stock ahead of earnings. The earnings call highlighted a CE Mark win for Flex and the filing of a 510(k) for Fit, reinforcing the company’s product pipeline and market expansion strategy.
What The Data Shows
The stock opened at $19.98, a 1.4% gap down from the previous close, but climbed steadily throughout the session. Volume reached 1.6 million shares, which is 1.6 times the 3-month average. The stock hit a 52-week high of $22.62 and closed the session near that level. Over the past 8 trading sessions, the stock has gained 10.4%, from $20.18 to $22.27. The 52-week range is $10.65 to $20.88, meaning the current price is well above its previous peak. The company remains unprofitable with a TTM EPS of -1.30 and a net margin of -10.7%, but revenue has grown 14.3% over the trailing twelve months.
What To Watch
MiniMed has no upcoming earnings date listed, but investors should monitor the breadth of analyst coverage and any further updates on the U.S. launch of Fit. The stock’s elevated valuation and recent price trend suggest continued attention to product progress and regulatory developments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MMED by the numbers
Last: $22.59Session: +11.48%7 sessions: +8.92%Coverage: 11 stories / 8 sourcesAI sentiment: 58/100 (bullish)Mkt cap: $5.6B52w: $10.65 to $20.88
The headlines behind the move
11d agoSeeking AlphaBULLISH 73Earnings
MiniMed projects ~10.5% fiscal 2027 organic revenue growth as Flex expands and Fit targets U.S. launch by summer 2027
MiniMed (MMED) Q1 FY2027 earnings call: 16% organic growth, Flex launch momentum, CE Mark win, Fit 510(k) filed, guidance raised.
11d agoMorningstarBULLISH 67Earnings
MiniMed Shares Gain as 1Q Sales Jump
Chief Executive Que Dallara called the quarter an excellent start to the fiscal year. "As our ecosystem continues to come together, we are well positioned to accelerate growth, strengthen our leadership in automated insulin delivery, and create long-term shareholder value," she added.
11d agoSeeking AlphaNEUTRAL 50Earnings
MiniMed Group, Inc. (MMED) Q1 2027 Earnings Call Transcript
MiniMed Group, Inc. (MMED) Q1 2027 Earnings Call September 1, 2026 8:45 AM EDTCompany ParticipantsRyan Weispfenning - Head of Investor RelationsQue Dallara...
11d agoYahoo TopBULLISH 68Earnings
MiniMed Group Q1 Earnings Call Highlights
MiniMed Group (NASDAQ:MMED) reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets. Chief Executive Officer
11d agoInvesting.com MarketsNEUTRAL 50General
Why is MiniMed stock surging today?
Why is MiniMed stock surging today?
11d agoInvesting.com Analyst RatingsBULLISH 61Analyst
StoneX reiterates Buy on MiniMed stock ahead of earnings
StoneX reiterates Buy on MiniMed stock ahead of earnings
12d agoThe FlyBEARISH 28Earnings
MiniMed reports Q1 EPS 0c, consensus 9c
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on MMED: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier MMED move explainers: 2026-09-02 · 2026-09-01 · 2026-08-26 · 2026-08-25